Cognitive impairment in the immune-mediated inflammatory diseases compared with age-matched controls: Systematic review and meta-regression
Authors' conclusion
People with IMIDs have moderate impairments across a range of cognitive domains. People with RA and SLE have similar magnitudes of impairment against their respective age-expected levels
Study context
- Population
- Observational studies of IMIDs (SLE, RA, axSpA, PsA, PsO) with healthy control comparison measuring cognitive ability65 IMID groups
- Participants
- 3,141 vs 9,333
- Comparison
- IMIDs vs healthy controls
- IMIDsn = 3,141
- Controlsn = 9,333reference
- Outcome
- SMD in cognitive assessments (overall, memory, complex attention/executive function, language/verbal fluency) between IMIDs and controls
Methodological detailsrandom-effects meta-analysis
- Random-effects meta-analysis
Pooled result
As reported in the abstract
Overall cognition
Each group vs controlsEstimate (95% CI)
IMIDs
SMD −0.57(−0.70 to −0.43)
IMIDs
SMD (complex attention/executive function) −0.57(−0.69 to −0.44)
IMIDs
SMD (memory) −0.55(−0.68 to −0.43)
IMIDs
SMD (language/verbal fluency) −0.51(−0.68 to −0.34)
Further pooled results
RA vs SLE (meta-regression)
- RA and SLE had similar magnitudes of cognitive impairment relative to age-expected levels
- NPSLE had larger impairment in overall cognition than RA
Original publication
Cognitive impairment in the immune-mediated inflammatory diseases compared with age-matched controls: Systematic review and meta-regression. Semin Arthritis Rheum. Published 12 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →